Freeline Therapeutics
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Show more...
CEO
Employees
236
Country
United States
ISIN
US35655L1070
WKN
000A3EEV1
Listings
0 Comments
Share your thoughts
FAQ
What is Freeline Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Freeline Therapeutics stocks are traded under the ticker 78F.STU.
How many employees does Freeline Therapeutics have?▼
As of September 05, 2026, the company has 236 employees.
In which sector is Freeline Therapeutics located?▼
Freeline Therapeutics operates in the Manufacturing sector.
When did Freeline Therapeutics complete a stock split?▼
The last stock split for Freeline Therapeutics was on May 12, 2023 with a ratio of 1:15.
Where is Freeline Therapeutics headquartered?▼
Freeline Therapeutics is headquartered in Stevenage, United States.